AGENCY USE
Our hypothesis was that needle microinjection of targeting vectors into normal human breast epithelial cells will result in efficient homologous recombination and allow the isolation of cell lines containing defined mutations in endogenous genes. We had two aims. Aim 1. Use microinjection to make stable Neo-resistant normal breast cells. Aim 2. Determine if the p53 gene can be targeted in normal human breast epithelial cells.
Aim 1 was successfully completed. We optimized conditions for neomycin selection after injection and showed that when neomycin-resistance plasmids were injected we could select for resistant clones using 7004g/ml G418. However, after injecting the p53 gene targeting vector provided by our collaborator, Dr. Sedivy, and screening 94 resistant clones, we were unable to identify any genes where the endogenous p53 gene was targeted (Table 1) suggesting that we would be unable to successfully achieve our goals for Aim 2.
This result could indicate that the use of microinjection as a delivery method is simply not significantly better than electroporation (i.e. our original hypothesis was incorrect) or that there was a specific problem with breast epithelial cells (i.e. injection is in fact a better delivery method but there is something wrong with our normal human breast cells that make the p53 gene unable to be targeted). To discriminate between these possibilities we attempted to target the Myc gene in rat fibroblasts. We chose these cells because Dr. Sedivy has already targeted them using electroporation to deliver the targeting vector (Hanson and Sedivy, 1995) . Thus we know that it is possible to target the Myc gene in these cells. Dr. Sedivy sent us his targeting vector, his parental (i.e. untargeted) cells (TGR1) and the cells that he successfully targeted using electroporation (HET cells). For both experiments in human breast cells and in rat fibroblasts, cells injected by both researchers (J. Thorburn and A. C. Lowe, nee Raukauskas) who were listed in the original grant application were combined to ensure that variation in injection technique between individuals was not responsible for the effects observed. We optimized DNA purification and PCR conditions so that we could successfully isolate and amplify genomic DNA from small numbers of cells growing as isolated clones. Table 1 .Results of injection experiments. While it was possible to obtain neomycinresistant clones, the targeting vectors were not integrated into the homologous genes. This was the case for both the p53 gene in human breast cells and for the Myc gene in rat fibroblasts. Because the same rat fibroblasts were successfully targeted previously using electroporation of the same Myc-targeting vector, we conclude that our injection approach is not better enough to justify further pursuit of this approach at this time.
These results are disappointing because although we were able to obtain G418-resistant clones at the anticipated rate (we predicted in our original application that is we were to inject about 1000 cells, we might obtain 50-100 resistant clones), we did not obtain any homologously targeted clones. We predicted that if our hypothesis was correct (i.e. that injection results in much more efficient homologous recombination than other delivery methods) we would need to test no more than 50-100 clones in order to obtain successfully targeted genes. Since we were able to test 94 clones in the first series of experiments in breast cells and a further 70 clones in fibroblasts in the second series of experiments, we would have expected to find a few clones with targeted alleles if our hypothesis was correct. Because we were unsuccessful even with the fibroblast line that was previously targeted using the same vector that we used, we suspect that this result is not specific to breast epithelial cells but instead indicates that our original hypothesis (i.e. that injection would be a significantly more efficient delivery method than electroporation) is not correct.
